Dan Bradbury

Daniel (Dan) Bradbury is a Life Sciences Executive with over 35 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market, and maximize shareholder value. He is the Chief Executive Officer, Chairman and Co-Founder of Equillium, Inc., a biopharmaceutical company based in La Jolla, CA, focused on developing products for autoimmune and inflammatory disorders, or immuno-inflammation, with high unmet medical need.

Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100.  He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals.  He serves on the board of directors of Equillium, Inc. (NASDAQ: EQ), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Biolinq, Inc. (Private), Castle Biosciences, Inc. (Private), DelNova, Inc. (Private), DiaVacs, Inc. (Private), Liquid Grids, Inc. (Private), ProSciento, Inc. (Private), Renova Therapeutics (Private) and Sensulin, Inc. (Private). He also serves on the board of the Riecken Community Libraries, the board of trustees of the Keck Graduate Institute, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management's Advisory Council, the board of ADCY5.org, the Pharming Group N.V. Commercial Advisory Board, the ProLynx, LLC Advisory Board and the Arctic Aurora Life Science Advisory Board.

Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.